Medigus Receives Approval From Israeli Ministry of Health to Market the MUSE(TM) System
OMER, Israel, July 28, 2015 - Medigus Ltd. (Nasdaq:MDGS) (TASE:MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technologies announced today that the company has received approval from the Israeli Ministry of Health (MOH) to market the Medigus Ultrasonic Surgical Endostapler, or MUSE™ system (formerly known as the SRS™ system) in Israel. The new MOH approval takes effect immediately and will expire in December 2016. The MUSE system is also FDA cleared and CE marked for the treatment of GERD in the United States and Europe, respectively. The new approval of the MOH was granted to Medigus following the expiration in February 2014 of the previously granted approval. "We are pleased to once again receive approval from Israel's Ministry of Health to market the MUSE system in Israel where our primary research and development occurs," said Chris Rowland, Chief Executive Officer of Medigus. "As an Israeli company expanding globally and a leader in the transition to minimally invasive endosurgical procedures, this approval allows us to leverage the abilities of leading surgeons and gastrointestinal physicians located close to our research and development facility to regularly perform procedures using the MUSE™ system while continuing to provide physicians around the world with leading non-invasive technologies." Prior to the approval of the MUSE system, anterior fundoplication (stapling of the upper part of the stomach, or fundus, to the lower esophageal sphincter) to treat GERD was typically performed surgically or laparoscopically, which required incisions. The MUSE system, however, is administered endoscopically, and therefore requires no incisions. Medigus intends to engage leading local physicians in Israel to perform patient procedures with the MUSE system, as well as to compile study related data with respect to the treatment.